La Jolla, Calif. — October 30, 2025 — Leads & Copy — MediciNova, Inc. (NASDAQ:MNOV) (Tokyo Stock Exchange: 4875) announced the publication of a research article in the Journal of Atherosclerosis and Thrombosis, demonstrating that MN-002, a metabolite of MN-001 (tipelukast), enhances cholesterol efflux in macrophages.
The study, titled “Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis,” was a collaboration with a Japanese research group specializing in lipid and cholesterol metabolism. MediciNova is currently conducting a Phase 2 study in hypertriglyceridemia, Type 2 DM, and NAFLD patients.
Yuichi Iwaki, M.D., Ph.D., MediciNova President and Chief Executive Officer, said the research provides insight into how MN-001 and MN-002 may influence cholesterol and lipid metabolism, and the company remains committed to exploring the therapeutic potential of MN-001.
Previous clinical studies have shown that MN-001 improved serum lipid profiles in patients with Non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, with notable effects in patients with type 2 diabetes (DM).
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. MediciNova has 11 programs in clinical development based on compounds MN-166 (ibudilast) and MN-001 (tipelukast).
Investor Contact:
David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com
Source: MediciNova, Inc.
